MAT-ID-2100862-V.1.0 (07/2021)
Pasien RAWAT INAP
Identifikasi
Muntah-muntah >>
Keluhan Utama 1 hari
Ny. SY, 67 tahun
IRT
alamat OKI Keluhan
Tambahan Batuk 1 minggu
Kepala
Konjungtiva anemis (-/-), sklera ikterik (-), pupil
Tanda Vital isokor Ø 4mm, refleks cahaya (+/+)
Keadaan Umum : Tampak Sakit Leher
Sedang JVP meningkat (-), pembesaran KGB (-)
Kesadaran : Compos Mentis Thoraks
TB/BB : 152 Cm / 58 Kg Simetris, retraksi (-), gerak dada tertinggal (-)
Imt : 25,1 Jantung : HR 78x/menit, murmur dan gallop (-)
TD : 120/80 Mmhg Paru : sonor, vesikuler normal, ronkhi (+) lap
tengah dan basal kedua paru, wheezing (-)
Nadi : 78 X/Menit
Abdomen
Pernafasan : 18 X/M Datar, lemas hepar-lien tidak teraba, BU (+)
Suhu : 36,3°C normal
Ekstremitas
Edema pretibial (-/-)
LAPORAN KASUS
Pemeriksaan Laboratorium
Hb 10,1 HbA1c 8.2
Glukosa darah
Ht 37 327
acak (mg/dL)
Leukosit 8100 Ur/Creatinin 16/0,76
Trombosit 350rb Na/K 129/3,3
Eritrosit 3 jt Trigliserida 100
AST 20 HDL 35
ALT 21 LDL 98
Kolesterol total 173
Gastropati
TB paru kasus baru
Diagnosis DM Tipe II overweight uncontrolled
Hiponatremia
Non-Farmakologis
Tatalaksana
Farmakologis
LAPORAN KASUS
PENATALAKSANAAN
Non-Farmakologis
Edukasi : diet dan lifestyle
modification
7
MONITORING PASIEN SELAMA RAWAT INAP
HbA1c (%)
< 80 mg/dL 80-130 mg/dL >130 mg/dL
HbA1c < 7% (atau sesuai dengan
(atau jika ada gejala
hipoglikemia) konsensus Perkeni baru)
Gula darah puasa/
Preprandial
capillary plasma 80 -110
glucose mg/dL
RWEInsulin
L
Turunkan Naikkan
Glukosa darah 1-2
jam PP kapiler/ Dosis Basal 2 2-3
Pertahankan 2-3
dosis
Peak Postprandial < 180
unit unit
capillary plasma mg/dL
glucose Setiap 3- 7 hari
Lantus XR 22 IU adalah maintenance dose untuk Ny.SY setelah melakukan metode titrasi 2 unit
setiap 3 hari
Titrasi Basal Insulin pada 3 bulan (12 minggu) pertama
merupakan prediktor glikemik kontrol jangka panjang1
A real-world, retrospective study1
40,627 insulin-naïve patients with T2DM1 6 countries worldwide (Europe & the US)1
Mean HbA1c at index date (initiation of basal insulin therapy) and during the 24
months after1
France Germany General HbA1c target in UK
Italy
UK
Spain
USA
General HbA1c target in France, Spain, USA
General HbA1c target in Germany, Italy
Pasien yang tidak
terkontrol glikemik
dalam 3 bulan
Mean HbA1c (%)
cenderung sulit
mencapai HbA1c ≤7.0%
pada bulan ke-24*1
21% 28%
pasien HbA1c pasien mencapai HbA1c
≤7.0% dalam 3 bulan1 ≤7.0% dalam 24 bulan1
*vs those with HbA1c already at ≤7.0% at 3 months (OR: 3.70 [95% CI: 3.41–4.00]).1
CI, confidence interval; OR, odds ratio; T2DM, Type 2 diabetes mellitus
1. Mauricio D, et al. Diabetes Obes Metab. 2017;19:1155–1164.
Gla 300 dapat dititrasi menggunakan berbagai algoritme dengan efikasi yang
baik
Gla-300 dapat dititrasi baik per hari, per 3 hari maupun per minggu dalam mencapai target FPG
• Adapted from: Riddle MC, et al. Diabetes Care. 2014;37:2755–62; Yki-Jarvinen H, et al. Diabetes Care. 2014;37:3735–43; Bolli GB, et al. Diabetes Obes Metab. 2015;17:386–94; Edelman S, et al.
ADA 77th Scientific Sessions 2017, late breaking poster 131-LB; Gerstein HC, et al. Diabet Med. 2006;23:736–42; Philis-Tsimikas A, et al. Adv Ther. 2013;30:607–22
Kontrol rawat jalan: smbg
14
Point of discussion: Mengapa pasien diberikan Gla-300?
15
Studi real world gla-300: pada pasien insulin naïve
ATOS: Observational study of clinical effectiveness of Gla-300 initiation after OAD in insulin-naïve T2DM (N=4527)in
Asia, Middle East, North Africa, Latin America, and Eastern Europe
6 months 12 months
HbA1c change from baseline* (95% CI) -1.51 (-1.54, -1.47) -1.89 (-1.99, -1.80)
• Data shown are mean ± SD and change from baseline is absolute mean. Mean baseline HbA1c was 9.3%. The interim analysis was undertaken when ≥50% of participants had 6-months’ follow-up data (cut-off: July
1, 2019). Safety analyses were undertaken in the eligible population (N=4527; those meeting the inclusion/exclusion criteria who started Gla-300 ±30 days from study start). Efficacy analyses were undertaken in
the evaluable population (n=3373; eligible patients with an HbA1c assessment at Month 6, of whom n=612 had a HbA1c assessment at Month 12). The primary endpoint was proportion of patients at predefined
individualized goals at month 6 but due to the observational nature of the study, data were not available for each endpoint in all participants; as such, population numbers varied slightly for each endpoint. The 6-
month period was defined as from the first treatment administration to visit 3 (Month 6) or treatment discontinuation, whichever occurred first; the 12-month treatment period was defined as from the first
treatment administration to visit 4 (Month 12) or treatment discontinuation, whichever occurred first. CI, confidence interval; FPG, fasting plasma glucose; SD, standard deviation; SMPG, self-monitored plasma
glucose; OAD, oral antidiabetic drugs; U, units.
Gla-300 lebih sedikit kenaikan berat badan vs Gla100 u/ml Beralih ke Gla-300, signifikan lebih sedikit kenaikan berat
pada bulan ke-6 dan seterusnya badan vs Gla100 u/ml pada saat pasien melakukan titrasi (BL
hingga minggu ke-12)
-88%*
-35% Weight-gain
lebih rendah
Weight-gain lebih bulan ke-6
rendah pada bulan Gla300
ke-6 Gla100
Gla300
Gla100
*Aims: To compare the efficacy and safety of insulin glargine 300 U/ml with glargine 100 U/ml in insulin-naïve people with T2DM using OADs. A multicentre, open-label, parallel-group study. Participants were randomized to Gla-300 or Gla-100
once daily for 6 months, discontinuing SUs and glinides, with a dose titration aimed at achieving FPG concentrations of 80–100mg/dl. The primary endpoint was change in HbA1c from baseline to month 6.
Kesimpulan